<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00371293</url>
  </required_header>
  <id_info>
    <org_study_id>442</org_study_id>
    <secondary_id>R01HL080076-01A1</secondary_id>
    <nct_id>NCT00371293</nct_id>
  </id_info>
  <brief_title>The Effects of Obesity and Obstructive Sleep Apnea on Inflammation and Heart Disease</brief_title>
  <official_title>Inflammatory Response to Sleep Apnea in Obese Subjects: The Cardiovascular Effects of Obstructive Sleep Apnea (COSA) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obstructive sleep apnea (OSA) is a serious sleep disorder in which a person's breathing is
      restricted during sleep. Obese individuals with OSA are at an increased risk of inflammation
      and heart conditions, but it is unknown whether this risk is related to the effects of OSA or
      obesity. This study will evaluate whether OSA or obesity plays the primary role in
      inflammation related to heart disease. The study will also determine the independent effects
      of OSA and obesity on insulin resistance and blood vessel function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OSA is a common sleep disorder that is characterized by a brief collapse of the upper airway
      during sleep. This blockage prevents air from flowing properly into the lungs and causes
      pauses in breathing. If left untreated, OSA can cause high blood pressure, memory problems,
      weight gain, impotency, and headaches. It is also associated with an increased risk of
      inflammation-related heart conditions. Obesity is common among individuals with OSA and it
      may also be associated with inflammation. It is not known, however, whether the increased
      risk of heart problems is caused primarily by the inflammatory effects of OSA or obesity.

      The most common treatment for OSA is continuous positive airway pressure (CPAP) therapy, in
      which a mask is worn over the nose during sleep. Air flows through the mask to maintain a
      level of pressure that keeps the throat open. The most common treatment for obesity is weight
      loss. This study will determine the primary cause of heart-related inflammation by evaluating
      the individual and combined effects of CPAP therapy and a weight loss program in treating
      obese individuals with OSA. The study will also determine the independent effects of these
      therapies on insulin resistance and blood vessel function (arterial stiffness, central
      arterial pressures).

      This study will enroll obese individuals with moderate to severe OSA for a total of 24 weeks.
      Potential participants will first take part in an overnight sleep study at the University of
      Pennsylvania sleep lab. Sensors will monitor body functions during the night, including brain
      and muscle activity, eye movement, heart rate, breathing effort, air flow, and blood oxygen
      levels. Eligible participants will then be randomly assigned to CPAP therapy, a weight loss
      program, or a combination of the two. Participants in the weight loss program will receive
      weekly dietary counseling and will be encouraged to decrease caloric intake and increase
      physical activity. Participants receiving CPAP therapy will use a CPAP machine each night
      while they sleep. Study visits for all participants will occur at baseline and Weeks 6, 12,
      and 24. Blood will be collected to measure levels of triglycerides, high-density lipoprotein
      (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and levels of C-reactive
      protein (CRP), which is an inflammation biomarker. Insulin resistance will be evaluated using
      a glucose tolerance test, and blood vessel function will be evaluated using a brachial artery
      reactivity test in which artery size and blood flow will be measured with an ultrasound.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inflammation</measure>
    <time_frame>Measured at Baseline and Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Insulin Resistance (Insulin Sensitivity Index, x10-4/Min−1/μU/ml)</measure>
    <time_frame>Measured at Baseline and Week 24</time_frame>
    <description>Assessed using the frequently sampled intravenous glucose tolerance test (FSIGTT) which evaluates blood glucose and insulin levels. Insulin sensitivity is estimated using the Bergman's minimal model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LDL Cholesterol Levels</measure>
    <time_frame>Measured at Baseline and Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Triglyceride Levels</measure>
    <time_frame>Measured at Baseline and Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HDL Cholesterol Levels</measure>
    <time_frame>Measured at Baseline and Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">181</enrollment>
  <condition>Sleep Apnea Syndromes</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive CPAP therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will take part in a weight loss program.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive CPAP therapy and take part in a weight loss program.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Weight Loss Program</intervention_name>
    <description>Participants in the weight loss program will receive weekly dietary counseling and will be encouraged to decrease caloric intake and increase physical activity.</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CPAP therapy</intervention_name>
    <description>Participants receiving CPAP therapy will use a CPAP machine each night while they sleep.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate to severe OSA (as defined by an apnea-hypopnea index [AHI] score greater than
             15 events per hour)

          -  Body mass index greater than 30 kg/m

          -  Baseline CRP greater than 1.0 mg/dL

        Exclusion Criteria:

          -  Predominant central sleep apnea

          -  Type 1 Diabetes

          -  Type 2 Diabetes associated with either: (a) unstable anti-diabetic therapy
             (anti-diabetic medication changes within past 3 months); (b) Hemoglobin A1C levels &gt;
             7%; (c) Inability to perform home blood glucose monitoring (fingerstick checks).

          -  Requires use of supplemental oxygen

          -  Acute coronary syndrome or stroke in the 3 months prior to study entry

          -  A high-risk occupation or motor vehicle driving record, as defined by a score of 10
             points or higher on an occupational and driving habits questionnaire

          -  Blood pressure greater than 160/95 mm Hg (may be re-screened after blood pressure
             control is obtained)

          -  Active infection, cancer, or chronic inflammatory disorder

          -  Use of systemic steroids

          -  Currently on an unstable dose of statin therapy (participants taking statins must be
             on a stable dose for at least 8 weeks prior to study entry)

          -  Simultaneous use of peroxisome proliferator-activated receptor (PPAR)-alpha (e.g.,
             gemfibrozil, fenofibrate) or PPAR-gamma (e.g., rosiglitazone, pioglitazone)

          -  Consumes more than 14 alcoholic drinks per week

          -  History of surgery in the 3 months prior to study entry

          -  Sustained ventricular or supraventricular tachycardia greater than 30 seconds during
             overnight sleep study

          -  Known left ventricular ejection fraction less than 30% or decompensated congestive
             heart failure requiring hospitalization in the year prior to study entry

          -  Any episode of decompensated respiratory function requiring hospitalization in the
             year prior to study entry

          -  Severe restless leg syndrome or chronic pain syndrome that gives rise to frequent
             awakenings at night, as determined during the overnight sleep study (individuals may
             still be enrolled if these sleep-disrupting disorders can be resolved prior to study
             entry)

          -  Pregnant or likely to become pregnant (i.e., pre-menopausal and not using a form of
             birth control)

          -  Severe depression, as defined by a score of 29 or higher on the Beck Depression Index,
             or suicidal ideation

          -  Serious medical or psychological condition that may compromise the participant's
             safety or successful participation in the study, in the opinion of the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julio A. Chirinos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania, Philadelphia Veterans Affairs Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Philadelphia Veterans Affairs Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2006</study_first_submitted>
  <study_first_submitted_qc>September 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2006</study_first_posted>
  <results_first_submitted>December 4, 2014</results_first_submitted>
  <results_first_submitted_qc>February 18, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 5, 2017</results_first_posted>
  <last_update_submitted>February 18, 2017</last_update_submitted>
  <last_update_submitted_qc>February 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Julio A. Chirinos</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Sleep Apnea</keyword>
  <keyword>C-Reactive Protein</keyword>
  <keyword>Obesity</keyword>
  <keyword>Insulin Resistance</keyword>
  <keyword>Arterial stiffness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CPAP</title>
          <description>Participants will receive CPAP therapy.
CPAP therapy: Participants receiving CPAP therapy will use a CPAP machine each night while they sleep.</description>
        </group>
        <group group_id="P2">
          <title>Weight Loss</title>
          <description>Participants will take part in a weight loss program.
Weight Loss Program: Participants in the weight loss program will receive weekly dietary counseling and will be encouraged to decrease caloric intake and increase physical activity.</description>
        </group>
        <group group_id="P3">
          <title>Combination</title>
          <description>Participants will receive CPAP therapy and take part in a weight loss program.
Weight Loss Program: Participants in the weight loss program will receive weekly dietary counseling and will be encouraged to decrease caloric intake and increase physical activity.
CPAP therapy: Participants receiving CPAP therapy will use a CPAP machine each night while they sleep.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="61"/>
                <participants group_id="P3" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CPAP</title>
          <description>Participants will receive CPAP therapy.
CPAP therapy: Participants receiving CPAP therapy will use a CPAP machine each night while they sleep.</description>
        </group>
        <group group_id="B2">
          <title>Weight Loss</title>
          <description>Participants will take part in a weight loss program.
Weight Loss Program: Participants in the weight loss program will receive weekly dietary counseling and will be encouraged to decrease caloric intake and increase physical activity.</description>
        </group>
        <group group_id="B3">
          <title>Combination</title>
          <description>Participants will receive CPAP therapy and take part in a weight loss program.
Weight Loss Program: Participants in the weight loss program will receive weekly dietary counseling and will be encouraged to decrease caloric intake and increase physical activity.
CPAP therapy: Participants receiving CPAP therapy will use a CPAP machine each night while they sleep.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="58"/>
            <count group_id="B2" value="61"/>
            <count group_id="B3" value="62"/>
            <count group_id="B4" value="181"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.8" spread="10"/>
                    <measurement group_id="B2" value="48.3" spread="10"/>
                    <measurement group_id="B3" value="49" spread="10"/>
                    <measurement group_id="B4" value="49" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Inflammation</title>
        <time_frame>Measured at Baseline and Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CPAP - Adherent</title>
            <description>Participants will receive CPAP therapy.
CPAP therapy: Participants receiving CPAP therapy will use a CPAP machine each night while they sleep.</description>
          </group>
          <group group_id="O2">
            <title>Weight Loss - Adherent</title>
            <description>Participants will take part in a weight loss program.
Weight Loss Program: Participants in the weight loss program will receive weekly dietary counseling and will be encouraged to decrease caloric intake and increase physical activity.</description>
          </group>
          <group group_id="O3">
            <title>Combination - Adherent</title>
            <description>Participants will receive CPAP therapy and take part in a weight loss program.
Weight Loss Program: Participants in the weight loss program will receive weekly dietary counseling and will be encouraged to decrease caloric intake and increase physical activity.
CPAP therapy: Participants receiving CPAP therapy will use a CPAP machine each night while they sleep.</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammation</title>
          <units>percentage of change in crp at week 24</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.47" lower_limit="-26.09" upper_limit="6.03"/>
                    <measurement group_id="O2" value="-37.45" lower_limit="-49.23" upper_limit="-22.94"/>
                    <measurement group_id="O3" value="-32.66" lower_limit="-47.14" upper_limit="-14.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Insulin Resistance (Insulin Sensitivity Index, x10-4/Min−1/μU/ml)</title>
        <description>Assessed using the frequently sampled intravenous glucose tolerance test (FSIGTT) which evaluates blood glucose and insulin levels. Insulin sensitivity is estimated using the Bergman’s minimal model.</description>
        <time_frame>Measured at Baseline and Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CPAP - Adherent</title>
            <description>Participants will receive CPAP therapy.
CPAP therapy: Participants receiving CPAP therapy will use a CPAP machine each night while they sleep.</description>
          </group>
          <group group_id="O2">
            <title>Weight Loss - Adherent</title>
            <description>Participants will receive take part in a weight loss program.
Weight Loss Program: Participants in the weight loss program will receive weekly dietary counseling and will be encouraged to decrease caloric intake and increase physical activity.</description>
          </group>
          <group group_id="O3">
            <title>Combination - Adherent</title>
            <description>Participants will receive CPAP therapy and take part in a weight loss program.
Weight Loss Program: Participants in the weight loss program will receive weekly dietary counseling and will be encouraged to decrease caloric intake and increase physical activity.
CPAP therapy: Participants receiving CPAP therapy will use a CPAP machine each night while they sleep.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Insulin Resistance (Insulin Sensitivity Index, x10-4/Min−1/μU/ml)</title>
          <description>Assessed using the frequently sampled intravenous glucose tolerance test (FSIGTT) which evaluates blood glucose and insulin levels. Insulin sensitivity is estimated using the Bergman’s minimal model.</description>
          <units>x10-4/min−1/μU/ml</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".06" lower_limit="-.34" upper_limit=".46"/>
                    <measurement group_id="O2" value=".43" lower_limit="-.04" upper_limit=".9"/>
                    <measurement group_id="O3" value=".74" lower_limit=".24" upper_limit="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in LDL Cholesterol Levels</title>
        <time_frame>Measured at Baseline and Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CPAP - Adherent</title>
            <description>Participants will receive CPAP therapy.
CPAP therapy: Participants receiving CPAP therapy will use a CPAP machine each night while they sleep.</description>
          </group>
          <group group_id="O2">
            <title>Weight Loss - Adherent</title>
            <description>Participants will take part in a weight loss program.
Weight Loss Program: Participants in the weight loss program will receive weekly dietary counseling and will be encouraged to decrease caloric intake and increase physical activity.</description>
          </group>
          <group group_id="O3">
            <title>Combination - Adherent</title>
            <description>Participants will receive CPAP therapy and take part in a weight loss program.
Weight Loss Program: Participants in the weight loss program will receive weekly dietary counseling and will be encouraged to decrease caloric intake and increase physical activity.
CPAP therapy: Participants receiving CPAP therapy will use a CPAP machine each night while they sleep.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in LDL Cholesterol Levels</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.76" lower_limit="-10.08" upper_limit="2.55"/>
                    <measurement group_id="O2" value="-9.25" lower_limit="-16.87" upper_limit="-1.6"/>
                    <measurement group_id="O3" value="-13.54" lower_limit="-22.03" upper_limit="-5.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Triglyceride Levels</title>
        <time_frame>Measured at Baseline and Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CPAP - Adherent</title>
            <description>Participants will receive CPAP therapy.
CPAP therapy: Participants receiving CPAP therapy will use a CPAP machine each night while they sleep.</description>
          </group>
          <group group_id="O2">
            <title>Weight Loss - Adherent</title>
            <description>Participants will take part in a weight loss program.
Weight Loss Program: Participants in the weight loss program will receive weekly dietary counseling and will be encouraged to decrease caloric intake and increase physical activity.</description>
          </group>
          <group group_id="O3">
            <title>Combination - Adherent</title>
            <description>Participants will receive CPAP therapy and take part in a weight loss program.
Weight Loss Program: Participants in the weight loss program will receive weekly dietary counseling and will be encouraged to decrease caloric intake and increase physical activity.
CPAP therapy: Participants receiving CPAP therapy will use a CPAP machine each night while they sleep.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Triglyceride Levels</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.1" lower_limit="-24.2" upper_limit="10"/>
                    <measurement group_id="O2" value="-23.2" lower_limit="-43.8" upper_limit="-2.6"/>
                    <measurement group_id="O3" value="-53" lower_limit="-76" upper_limit="-30.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HDL Cholesterol Levels</title>
        <time_frame>Measured at Baseline and Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CPAP - Adherent</title>
            <description>Participants will receive CPAP therapy.
CPAP therapy: Participants receiving CPAP therapy will use a CPAP machine each night while they sleep.</description>
          </group>
          <group group_id="O2">
            <title>Weight Loss - Adherent</title>
            <description>Participants will take part in a weight loss program.
Weight Loss Program: Participants in the weight loss program will receive weekly dietary counseling and will be encouraged to decrease caloric intake and increase physical activity.</description>
          </group>
          <group group_id="O3">
            <title>Combination - Adherent</title>
            <description>Participants will receive CPAP therapy and take part in a weight loss program.
Weight Loss Program: Participants in the weight loss program will receive weekly dietary counseling and will be encouraged to decrease caloric intake and increase physical activity.
CPAP therapy: Participants receiving CPAP therapy will use a CPAP machine each night while they sleep.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HDL Cholesterol Levels</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.62" lower_limit="-2.74" upper_limit="1.5"/>
                    <measurement group_id="O2" value="0.71" lower_limit="-1.85" upper_limit="3.27"/>
                    <measurement group_id="O3" value="0.49" lower_limit="-2.37" upper_limit="3.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Clustered data collection. Data on separate Adverse Event Terms not available. All adverse events were non serious so they are reported under Other Adverse Events.</desc>
      <group_list>
        <group group_id="E1">
          <title>CPAP</title>
          <description>Participants will receive CPAP therapy.
CPAP therapy: Participants receiving CPAP therapy will use a CPAP machine each night while they sleep.</description>
        </group>
        <group group_id="E2">
          <title>Combination</title>
          <description>Participants will receive CPAP therapy and take part in a weight loss program.
Weight Loss Program: Participants in the weight loss program will receive weekly dietary counseling and will be encouraged to decrease caloric intake and increase physical activity.
CPAP therapy: Participants receiving CPAP therapy will use a CPAP machine each night while they sleep.</description>
        </group>
        <group group_id="E3">
          <title>Weight Loss</title>
          <description>Participants will take part in a weight loss program.
Weight Loss Program: Participants in the weight loss program will receive weekly dietary counseling and will be encouraged to decrease caloric intake and increase physical activity.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>High Blood Pressure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Swelling in legs and ankles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Leg Cramps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Type II Diabetes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye Irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomited during IVGTT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Intestinal Cramping</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Self Committed to Hospital</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Right Flank Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Motor Vehicle Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Tendonitis of Shoulder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Knee Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Pain in ankle/ lower back</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Sprained Wrist/ Bruised Knee</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>New diagnosis of fibromyalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Right Shoulder Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Ankle Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>&quot;Shakiness&quot; After IVGTT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Panic Attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Possible Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Abdominal Pain/ Kidney Stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <description>Nasal or sinus congestion</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Flu</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Nostril Irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Worsening of Respiratory Allergy Symptoms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Burning Sensation after IVGTT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Lump at site of IV</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Bruising/Tenderness- IV</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Rash from Lead</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Knee Replacement Surgery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Wisdom Teeth Removal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Rotator Cuff Surgery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Tooth Extraction and Implant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Julio Chirinos</name_or_title>
      <organization>UPenn</organization>
      <phone>2158235800</phone>
      <email>julio.chirinos@uphs.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

